Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

H.C. Wainwright Reaffirms Their Buy Rating on Opko Health (OPK)

Tipranks - Tipranks - Tue Mar 3, 5:40AM CST

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Opko Health today and set a price target of $3.00.

Claim 50% Off TipRanks Premium

According to TipRanks, Chen is a 3-star analyst with an average return of 2.0% and a 42.11% success rate. Chen covers the Healthcare sector, focusing on stocks such as Alpha Tau Medical Ltd, RegenXBio, and OKYO Pharma Limited Sponsored ADR.

In addition to H.C. Wainwright, Opko Health also received a Buy from Piper Sandler’s Edward Tenthoff in a report issued on February 27. However, on the same day, TipRanks – xAI reiterated a Hold rating on Opko Health (NASDAQ: OPK).

See the top stocks recommended by analysts >>

Based on Opko Health’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $148.5 million and a GAAP net loss of $31.3 million. In comparison, last year the company earned a revenue of $183.64 million and had a net profit of $14.03 million

Read More on OPK:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).